1258544-93-2Relevant academic research and scientific papers
Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics
Henderson, Jaclyn L.,Sawant-Basak, Aarti,Tuttle, Jamison B.,Dounay, Amy B.,McAllister, Laura A.,Pandit, Jayvardhan,Rong, Suobao,Hou, Xinjun,Bechle, Bruce M.,Kim, Ji-Young,Parikh, Vinod,Ghosh, Somraj,Evrard, Edelweiss,Zawadzke, Laura E.,Salafia, Michelle A.,Rago, Brian,Obach, Ronald S.,Clark, Alan,Fonseca, Kari R.,Chang, Cheng,Verhoest, Patrick R.
, p. 125 - 129 (2013/03/13)
A series of kynurenine aminotransferase II (KAT II) inhibitors has been developed replacing the hydroxamate motif with a bioisostere. Triazolinones or triazoles have proven to be effective replacements with significantly improved pharmacokinetics includin
Bicyclic And Tricyclic Compounds As KAT II Inhibitors
-
Page/Page column 36-37, (2010/12/31)
Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
